Scholars@Duke

Omalizumab use during pregnancy for CIU: a tertiary care experience.

Publication ,  Journal Article
Cuervo-Pardo, L; Barcena-Blanch, M; Radojicic, C
Published in: Eur Ann Allergy Clin Immunol
July 2016
Link to item

The treatment of antihistamine and steroid resistant Chronic Idiopathic Urticaria (CIU) during pregnancy poses a challenge due to teratogenicity of immunosuppressants. Omalizumab is a recently FDA approved therapy for CIU and is classified as pregnancy category B. We present an initial series of subjects treated at a tertiary care center for antihistamine and steroid resistant CIU with omalizumab who became pregnant during therapy.

Duke Scholars

Cristine Radojicic
Author Cristine Radojicic Medicine, Pulmonary, Allergy, and Critical Care Medicine

Published In

Eur Ann Allergy Clin Immunol

ISSN

1764-1489

Publication Date

July 2016

Volume

48

Issue

4

Start / End Page

145 / 146

Location

Italy

Related Subject Headings

  • Urticaria
  • Treatment Outcome
  • Tertiary Care Centers
  • Risk Assessment
  • Remission Induction
  • Pregnancy Complications
  • Pregnancy
  • Omalizumab
  • Ohio
  • Immunosuppressive Agents
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Cuervo-Pardo, L., Barcena-Blanch, M., & Radojicic, C. (2016). Omalizumab use during pregnancy for CIU: a tertiary care experience. Eur Ann Allergy Clin Immunol, 48(4), 145–146.
Cuervo-Pardo, L., M. Barcena-Blanch, and C. Radojicic. “Omalizumab use during pregnancy for CIU: a tertiary care experience.” Eur Ann Allergy Clin Immunol 48, no. 4 (July 2016): 145–46.
Cuervo-Pardo L, Barcena-Blanch M, Radojicic C. Omalizumab use during pregnancy for CIU: a tertiary care experience. Eur Ann Allergy Clin Immunol. 2016 Jul;48(4):145–6.
Cuervo-Pardo, L., et al. “Omalizumab use during pregnancy for CIU: a tertiary care experience.” Eur Ann Allergy Clin Immunol, vol. 48, no. 4, July 2016, pp. 145–46.
Cuervo-Pardo L, Barcena-Blanch M, Radojicic C. Omalizumab use during pregnancy for CIU: a tertiary care experience. Eur Ann Allergy Clin Immunol. 2016 Jul;48(4):145–146.

Published In

Eur Ann Allergy Clin Immunol

ISSN

1764-1489

Publication Date

July 2016

Volume

48

Issue

4

Start / End Page

145 / 146

Location

Italy

Related Subject Headings

  • Urticaria
  • Treatment Outcome
  • Tertiary Care Centers
  • Risk Assessment
  • Remission Induction
  • Pregnancy Complications
  • Pregnancy
  • Omalizumab
  • Ohio
  • Immunosuppressive Agents